Revolution Medicines (RVMD) announced the first patient has been dosed in RASolve 301, a global, randomized, open-label Phase 3 clinical trial. RASolve 301 will evaluate the safety and efficacy of daraxonrasib, a RAS multi-selective inhibitor, in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer, NSCLC, compared to docetaxel chemotherapy. RASolve 301 is anticipated to enroll approximately 420 patients with NSCLC worldwide who have received one to two prior lines of therapy for the treatment of advanced disease including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target lowered to $72 from $73 at H.C. Wainwright
- Promising Developments in Revolution Medicines’ RAS(ON) Pipeline for NSCLC Treatment
- Revolution Medicines’ Earnings Call: Optimism Amid Rising Costs
- Revolution Medicines price target lowered to $80 from $87 at Guggenheim
- Revolution Medicines price target raised to $75 from $70 at Oppenheimer